BRPI0814777A2 - Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica. - Google Patents

Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica.

Info

Publication number
BRPI0814777A2
BRPI0814777A2 BRPI0814777-9A2A BRPI0814777A BRPI0814777A2 BR PI0814777 A2 BRPI0814777 A2 BR PI0814777A2 BR PI0814777 A BRPI0814777 A BR PI0814777A BR PI0814777 A2 BRPI0814777 A2 BR PI0814777A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
neoplasm
treating
pharmaceutical
Prior art date
Application number
BRPI0814777-9A2A
Other languages
English (en)
Inventor
Stanley Dawes Chamberlain
Felix Deanda
Roseanne Gerding
Masaichi Hasegawa
Kevin Kuntz
John Brad Shotwell
Joseph Wilson
Huangshu John Lei
Yasushi Miyazaki
Naohiko Nishigaki
Samarjit Patnaik
Aniko Redman
Kirk Stevens
Bin Yang
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BRPI0814777A2 publication Critical patent/BRPI0814777A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
BRPI0814777-9A2A 2007-08-08 2008-08-06 Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica. BRPI0814777A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95464907P 2007-08-08 2007-08-08
US3008208P 2008-02-20 2008-02-20
PCT/US2008/072267 WO2009020990A1 (en) 2007-08-08 2008-08-06 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] benzamide derivatives as igf-1r inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0814777A2 true BRPI0814777A2 (pt) 2015-03-03

Family

ID=39797927

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814777-9A2A BRPI0814777A2 (pt) 2007-08-08 2008-08-06 Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica.

Country Status (10)

Country Link
US (1) US7981903B2 (pt)
EP (1) EP2188292B1 (pt)
JP (1) JP5298128B2 (pt)
CN (1) CN101827848B (pt)
AR (1) AR068054A1 (pt)
BR (1) BRPI0814777A2 (pt)
CL (1) CL2008002319A1 (pt)
ES (1) ES2424977T3 (pt)
RU (1) RU2472797C2 (pt)
WO (1) WO2009020990A1 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
JP5400791B2 (ja) * 2007-12-04 2014-01-29 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 置換ジヒドロプテリジン−６−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
SI2428508T1 (sl) 2009-05-08 2016-04-29 Astellas Pharma Inc. Diamino heterociklična karboksamidna spojina
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2011032050A2 (en) * 2009-09-11 2011-03-17 Trius Therapeutics, Inc. Gyrase inhibitors
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
GB201106817D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
FR2980477B1 (fr) * 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
FR2984318B1 (fr) 2011-12-16 2014-06-27 Oreal Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines cationiques, composition tinctoriale en comprenant, procedes et utilisations
FR2984323B1 (fr) * 2011-12-16 2019-08-30 L'oreal Coupleur de structure 7 amino-1,2,3,4-tetrahydroquinoleines, composition tinctoriale en comprenant, procedes et utilisations
CA2861010A1 (en) 2012-01-13 2013-07-18 Xiao Xu Heterocyclic compounds and uses as anticancer agents
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
UY34807A (es) 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
CN103655572A (zh) * 2012-09-17 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804382A (zh) * 2012-11-05 2014-05-21 韩文毅 一类治疗湿疹的化合物及其用途
BR112015010221B1 (pt) * 2012-11-06 2022-09-13 Shanghai Fochon Pharmaceutical Co., Ltd. Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
NZ715687A (en) 2013-07-11 2019-04-26 Acea Biosciences Inc Pyrimidine derivatives as kinase inhibitors
ES2883289T3 (es) 2013-12-20 2021-12-07 Astex Therapeutics Ltd Compuestos heterocíclicos bicíclicos y sus usos en terapia
JP2017510628A (ja) * 2014-03-13 2017-04-13 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 縮合ピリミジン系ヒドロキサメート誘導体
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX373150B (es) * 2014-03-26 2020-04-21 Astex Therapeutics Ltd Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
AU2016219102B2 (en) * 2015-02-13 2020-10-15 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US10259816B2 (en) * 2015-04-24 2019-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
AU2016328693B2 (en) 2015-09-23 2021-03-11 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
DK3353177T3 (da) 2015-09-23 2020-08-24 Janssen Pharmaceutica Nv Tricykliske heterocykler til behandling af cancer
KR20180067584A (ko) 2015-10-09 2018-06-20 아세아 테라퓨틱스 인코포레이티드 피롤로피리미딘 키나아제 억제제의 약학적 염, 물리적 형태 및 조성물, 및 이들의 제조 방법
CN107793417B (zh) * 2016-09-05 2020-06-09 复旦大学 吡咯并[2,3-d]嘧啶类化合物及其盐，及制备方法和药用用途
CN106432054A (zh) * 2016-09-17 2017-02-22 青岛云天生物技术有限公司 制备4‑（哌啶‑3‑基）苯胺的方法
EP3528816A4 (en) * 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
MA46620A (fr) * 2016-10-28 2021-05-26 Bristol Myers Squibb Co Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
AU2017408099A1 (en) 2017-04-07 2019-11-07 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
US11339157B1 (en) 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
AU2018397483A1 (en) * 2017-12-28 2020-08-13 Development Center For Biotechnology Heterocycle compounds as Tyro3, Axl and Mertk (TAM) family of receptor tyrosine kinase inhibitors
CN110357889B (zh) * 2018-04-09 2022-03-15 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
EP3932922A4 (en) 2019-02-25 2022-05-11 ShanghaiTech University SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE
EP3958865B1 (en) 2019-04-24 2025-12-10 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2020216773A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
GEAP202415804A (en) 2019-04-24 2024-02-12 Bayer Ag 4h-pyrrolo[3,2-c]pyridin-4-one compounds
CN110294721A (zh) * 2019-07-22 2019-10-01 安庆缘启医药科技有限公司 1-乙酰基-4-[3-(甲基氧基)-4-硝基苯基]哌嗪的合成工艺
WO2021023233A1 (zh) 2019-08-05 2021-02-11 上海科技大学 Egfr蛋白降解剂及其抗肿瘤应用
BR112022003663A2 (pt) 2019-08-28 2022-05-24 Horizon Therapeutics Ireland Dac Método para tratar oftalmopatia tireoidiana (ted) em um indivíduo com ted; método para reduzir proptose em pelo menos 2 mm em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de diplopia em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de oftalmopatia tireoidiana (ted); método para reduzir proptose em um olho em um indivíduo com oftalmopatia tireoidiana (ted); método para reduzir pontuação de atividade clínica (cas) de oftalmopatia tireoidiana (ted); método para a) reduzir proptose em pelo menos 2 mm e b) reduzir a pontuação de atividade clínica (cas) em um indivíduo com oftalmopatia tireoidiana (ted); e método para melhorar a qualidade de vida em um indivíduo com oftalmopatia tireoidiana (ted)
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives
WO2021198020A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
CN116239597B (zh) * 2021-12-07 2024-08-06 中国科学院上海药物研究所 一种嘧啶并吡咯类衍生物及其药用组合物和应用
CN114230524A (zh) * 2021-12-28 2022-03-25 南通大学 (5-氟-2-苯胺嘧啶-4-基)氨基-n-羟基苯甲酰胺衍生物及其制备方法与应用
CN114031559A (zh) * 2021-12-28 2022-02-11 南通大学 基于芳基含氮杂环修饰的5-氟-嘧啶二胺苯甲酸酯及其制备方法与应用
CN114349670A (zh) * 2022-02-17 2022-04-15 吉林大学 一种含侧链砜基结构的二胺单体、聚酰亚胺及其制备方法和应用
CN115089589A (zh) * 2022-06-10 2022-09-23 杭州市肿瘤医院 激酶抑制剂gsk1838705a在制备抑制食管癌的药物中的应用
WO2025014774A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating active and chronic thyroid eye disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI944602A0 (fi) * 1992-04-03 1994-10-03 Upjohn Co Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
DE60320933D1 (de) * 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
NZ585188A (en) 2003-08-15 2011-09-30 Novartis Ag 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US7338957B2 (en) * 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1713806B1 (en) * 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0514094A (pt) * 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
JP5400388B2 (ja) * 2005-12-15 2014-01-29 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼインヒビターおよびその利用

Also Published As

Publication number Publication date
WO2009020990A1 (en) 2009-02-12
US7981903B2 (en) 2011-07-19
JP2010535798A (ja) 2010-11-25
US20100204196A1 (en) 2010-08-12
EP2188292B1 (en) 2013-05-29
EP2188292A1 (en) 2010-05-26
AR068054A1 (es) 2009-11-04
RU2010103160A (ru) 2011-09-20
JP5298128B2 (ja) 2013-09-25
CN101827848A (zh) 2010-09-08
ES2424977T3 (es) 2013-10-10
RU2472797C2 (ru) 2013-01-20
CL2008002319A1 (es) 2009-01-02
CN101827848B (zh) 2012-11-07

Similar Documents

Publication Publication Date Title
BRPI0814777A2 (pt) Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica.
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI0907976A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI1010937A2 (pt) composto, uso de um composto, e, método para tratar câncer
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0909691A2 (pt) Composto, método para preparar um composto, e, composição farmacêutica
BRPI0811898A2 (pt) composto, composição farmacêutica, métodos para tratar um neoplasma suscetível e um câncer em um mamífero, processo para preparar um composto, e, uso de um composto.
BRPI0815591A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0908883A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0909198A2 (pt) composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
BRPI0818448A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5.
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
BR112012001030A2 (pt) método para tratar a degeneração macular, e, uso de um composto.
BRPI0914790A2 (pt) uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
BRPI0811238A2 (pt) Composto, uso de um composto, composição farmacêutica, e, método para tratar um distúrbio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.